Nicholas Company, Inc. Vertex Pharmaceuticals Inc Transaction History

Nicholas Company, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $6.32 Million - $7.36 Million	-30,510 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$207.01 - $276.09 $10,350 - $13,804	50 Added 0.16%	30,510 $7.21 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $7,669 - $9,093	30 Added 0.1%	30,460 $8.29 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $1.02 Million - $1.34 Million	-4,545 Reduced 12.99%	30,430 $8.83 Million
Q1 2020 May 13, 2020	SELL	$199.77 - $247.81 $22,973 - $28,498	-115 Reduced 0.33%	34,975 $8.32 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $8,335 - $11,195	-50 Reduced 0.14%	35,090 $7.68 Million
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $14,814 - $17,133	-90 Reduced 0.26%	35,140 $6.44 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $860,454 - $988,756	5,130 Added 17.04%	35,230 $6.79 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $424,045 - $494,583	2,910 Added 10.7%	30,100 $5.12 Million
Q1 2018 May 14, 2018	BUY	$151.6 - $177.13 $4.12 Million - $4.82 Million	27,190 New	27,190 $4.43 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Nicholas Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Nicholas Company, Inc. with notifications on news.